Mammoth Biosciences
COVID-19 drove an investment boom that pushed diagnostics innovation, but newer technologies could be in a precarious position as public funding and test sales slow.
IDbyDNA Nabs Additional Funding for Gene Editing Dx, Biosurveillance Tech
In collaboration with other firms, IDbyDNA is using precision metagenomics to develop a next-generation device for diagnostic testing of emerging infectious diseases.
Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets FDA EUA
The high-throughput test combines CRISPR technology with an automated liquid handling platform from Agilent.
Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test
The diagnostic is composed of Agilent's Bravo automation workstation and Mammoth's DETECTR BOOST SARS-CoV-2 assay.
DARPA Awards $36.7M to Six Organizations for Gene Editing-Based Dx, Biosurveillance Tech
The contract was awarded under DARPA's Detect It with Gene Editing Technologies program, which aims to create a device to detect at least 10 pathogens.